Immunotherapies that target the PD1–PDL1 axis continue to generate solid clinical data, and fresh combination trial results offer tantalizing hints of greater effectiveness to come.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect
European Radiology Open Access 30 November 2018
-
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Cell Discovery Open Access 07 March 2017
-
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
Scientific Reports Open Access 26 July 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 12, 489–492 (2013). https://doi.org/10.1038/nrd4066
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4066
This article is cited by
-
Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect
European Radiology (2019)
-
The era of immunogenomics/immunopharmacogenomics
Journal of Human Genetics (2018)
-
Nobel Prize in Physiology or Medicine – 2018
Resonance (2018)
-
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Cell Discovery (2017)
-
Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model
Molecular Imaging and Biology (2017)